gene therapy sarepta - Search News

News

Sarepta shares rebound

Reuters on MSN · 2d

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

The American Journal of Manag… · 13h

FDA Recommends Sarepta Resume DMD Gene Therapy Shipments for Ambulatory Patients

Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a voluntary pause.

The Associated Press on MSN · 3d

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

9d

Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

Shipments will halt by close of business Tuesday evening, the company said. Sarepta had initially rejected the agency’s ...

1d

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results